Review
Treatment of Alzheimer's disease with cholinergic drugs
Affiliations
- PMID: 2004862
Item in Clipboard
Review
Treatment of Alzheimer's disease with cholinergic drugs
Int J Clin Pharmacol Ther Toxicol.
1991 Jan.
Abstract
Several cholinergic drugs have been experimentally used to treat the cognitive and behavioral deficits associated with Alzheimer's disease. Unfortunately the results have been somewhat disappointing. The cholinergic drugs are also prone to produce serious side effects. Experience with these drugs lead us to conclude that cholinergic drugs alone may not be the answer to treat Alzheimer disease patients. There seems to be a need to develop drug(s) which could affect several neurotransmitter or neuromodulator systems. Neuroendocrine changes induced by these drugs may be useful biological markers in estimating their central effects.
Similar articles
-
The treatment of cognitive impairment in Alzheimer's disease: beyond the cholinergic approach.Psychiatr Clin North Am. 1991 Jun;14(2):461-82. Psychiatr Clin North Am. 1991. PMID: 2062728 Review.
-
[Galantamine: a novel cholinergic agent for Alzheimer's disease].Neurologia. 2002 Oct;17(8):429-36. Neurologia. 2002. PMID: 12396973 Spanish.
-
[The effects of cholinergic preparations in Alzheimer's disease].Farmakol Toksikol. 1991 May-Jun;54(3):4-10. Farmakol Toksikol. 1991. PMID: 1915820 Review. Russian. No abstract available.
-
[Cholinergic treatment strategies in Alzheimer's disease].Nervenarzt. 1986 Oct;57(10):558-69. Nervenarzt. 1986. PMID: 3785472 German. No abstract available.
-
Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.Arch Intern Med. 1995 Sep 11;155(16):1766-72. Arch Intern Med. 1995. PMID: 7654110 Clinical Trial.
Cited by
-
Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.CNS Drugs. 2002;16(7):485-500. doi: 10.2165/00023210-200216070-00005. CNS Drugs. 2002. PMID: 12056923
-
PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist.Mol Neurobiol. 1994 Aug-Dec;9(1-3):93-106. doi: 10.1007/BF02816108. Mol Neurobiol. 1994. PMID: 7888109
-
Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease.Naunyn Schmiedebergs Arch Pharmacol. 1993 Feb;347(2):214-9. doi: 10.1007/BF00169270. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 8097284
-
Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction.Br J Pharmacol. 1994 Apr;111(4):1103-10. doi: 10.1111/j.1476-5381.1994.tb14858.x. Br J Pharmacol. 1994. PMID: 8032596 Free PMC article.
-
Pharmacokinetics of physostigmine in man following a single application of a transdermal system.Br J Clin Pharmacol. 1995 Jan;39(1):59-63. doi: 10.1111/j.1365-2125.1995.tb04410.x. Br J Clin Pharmacol. 1995. PMID: 7756100 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical